Literature DB >> 17200963

Chemotherapy for metastatic melanoma: time for a change?

Helen J Gogas1, John M Kirkwood, Vernon K Sondak.   

Abstract

Melanoma is a neoplasm with a rising incidence. Early-stage melanoma is curable, but advanced, metastatic melanoma almost uniformly is fatal, and patients with such advanced disease have a short median survival. Systemic therapy remains unsatisfactory, inducing complete durable responses in a small minority of patients. For the current review, the authors focused on the current role of cytotoxic chemotherapy in the treatment of metastatic melanoma and the future prospects for improvements for multiagent chemotherapy and chemotherapy combined with immunomodulatory and/or molecularly targeted agents. They discuss roles of single-agent chemotherapy, combination chemotherapy, combinations of chemotherapy with immunomodulatory or hormone agents, biochemotherapy, and combination chemotherapy with targeted therapies. (c) 2007 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200963     DOI: 10.1002/cncr.22427

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  73 in total

1.  Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.

Authors:  Christina Kim; Christopher W Lee; Laurel Kovacic; Amil Shah; Richard Klasa; Kerry J Savage
Journal:  Oncologist       Date:  2010-06-10

2.  Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.

Authors:  Hla Win-Piazza; Valentina E Schneeberger; Liwei Chen; Daniele Pernazza; Harshani R Lawrence; Said M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Cancer Lett       Date:  2012-02-01       Impact factor: 8.679

3.  Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Authors:  Ali R Jazirehi; James S Economou
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

4.  Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Authors:  Thomas Metzner; Alexandra Bedeir; Gerlinde Held; Barbara Peter-Vörösmarty; Sara Ghassemi; Christine Heinzle; Sabine Spiegl-Kreinecker; Brigitte Marian; Klaus Holzmann; Bettina Grasl-Kraupp; Christine Pirker; Michael Micksche; Walter Berger; Petra Heffeter; Michael Grusch
Journal:  J Invest Dermatol       Date:  2011-07-14       Impact factor: 8.551

Review 5.  Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites.

Authors:  Amod A Sarnaik; Jonathan S Zager; Vernon K Sondak
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

6.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

7.  Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.

Authors:  Jianjun Chen; Zhao Wang; Yan Lu; James T Dalton; Duane D Miller; Wei Li
Journal:  Bioorg Med Chem Lett       Date:  2008-05-01       Impact factor: 2.823

8.  Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis.

Authors:  Vladimir N Ivanov; Michael A Partridge; Sarah X L Huang; Tom K Hei
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

9.  Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.

Authors:  Katharine M Hardy; Luigi Strizzi; Naira V Margaryan; Kanika Gupta; George F Murphy; Richard A Scolyer; Mary J C Hendrix
Journal:  Mol Cancer Res       Date:  2015-03-12       Impact factor: 5.852

10.  The potential effect of patulin on mice bearing melanoma cells: an anti-tumour or carcinogenic effect?

Authors:  Manel Boussabbeh; Intidhar Ben Salem; Karima Rjiba-Touati; Chedy Bouyahya; Fadwa Neffati; Mohamed Fadhel Najjar; Hassen Bacha; Salwa Abid-Essefi
Journal:  Tumour Biol       Date:  2015-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.